Glycopyrrolate + Indacaterol Suppliers & Bulk Manufacturers
Available Forms: Inhalation powder delivered via Neohaler device/Breezhaler device
Available Strengths: Ultibro Breezhaler: Indacaterol 85 mcg + Glycopyrronium 43 mcg
Reference Brands: Utibron Neohaler(Dis.cntd in US-2020); Ultibro Breezhaler(EU)
Category:
Respiratory Disorder
Glycopyrrolate + Indacaterol is a dual bronchodilator used for long-term COPD management. It combines a LAMA and LABA to improve breathing and reduce symptoms. Sold as Ultibro Breezhaler in the EU, it offers once-daily relief and better lung function, but is not for acute symptom relief.
Glycopyrrolate + Indacaterol is available in Inhalation powder delivered via Neohaler device/Breezhaler device
and strengths such as Ultibro Breezhaler: Indacaterol 85 mcg + Glycopyrronium 43 mcg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Glycopyrrolate + Indacaterol is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Glycopyrrolate + Indacaterol can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Glycopyrrolate + Indacaterol is a dual bronchodilator combination used for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Glycopyrrolate is a long-acting muscarinic antagonist (LAMA), while Indacaterol is a long-acting beta2-agonist (LABA). Together, they provide effective, once-daily bronchodilation, improving lung function and reducing COPD symptoms like breathlessness. Marketed under brand names such as Ultibro Breezhaler in the EU and previously as Utibron Neohaler in the US, this inhalation therapy offers enhanced respiratory relief. It is not intended for acute symptom relief but plays a vital role in COPD management by optimizing airflow and improving patients’ quality of life.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing